A provider-focused briefing on the Cardizem (Diltiazem) shortage in 2026: injectable supply timeline, oral availability, prescribing considerations, and tools.
Diltiazem supply issues have been a persistent challenge for years, particularly in the acute care setting. As we move through 2026, providers need a clear picture of what's available, what's constrained, and how to keep patients covered. This briefing covers the current status, timeline, clinical implications, and practical tools for managing Diltiazem access.
The Diltiazem shortage story spans over a decade:
Status: Ongoing shortage. This remains one of the most protracted drug shortages in the U.S. With only two active suppliers (Hikma and Pfizer) and allocation-based distribution, hospitals should maintain contingency protocols.
Clinical impact: Emergency departments and ICUs relying on IV Diltiazem for acute rate control of atrial fibrillation/flutter and PSVT may need to implement therapeutic substitution protocols. Common alternatives in the acute setting include IV Verapamil, IV Amiodarone, IV Esmolol, and IV Metoprolol, depending on the clinical scenario and institutional guidelines.
Status: Generally available. Generic oral Diltiazem (IR tablets and ER capsules/tablets) is produced by multiple manufacturers including Teva, Mylan, Lupin, and Aurobindo. However, providers should be aware of several practical barriers patients face:
Given the supply landscape, consider these practical adjustments:
Understanding patient cost barriers is essential for adherence:
For patients struggling with costs, refer them to savings resources including discount cards and patient assistance programs. Providers can also review our provider's guide to helping patients save on Cardizem.
The injectable Diltiazem shortage is unlikely to resolve quickly. With only two active manufacturers and no publicly announced new market entrants, allocation-based distribution will likely continue through 2026 and beyond. Hospitals should maintain and regularly update their therapeutic substitution protocols.
For oral Diltiazem, the outlook is more optimistic. Multiple generic manufacturers ensure a competitive supply, and the drug's off-patent status keeps prices accessible. The main challenge remains the non-interchangeability of ER formulations, which creates friction at the pharmacy level. Providers can reduce this friction by prescribing with formulation flexibility when clinically appropriate.
The Diltiazem supply situation requires awareness but not alarm — at least for oral formulations. By understanding the formulation landscape, prescribing with flexibility, and connecting patients with tools like Medfinder, providers can minimize disruptions to Diltiazem therapy. For patients who report difficulty filling their prescriptions, the issue is often solvable with a formulation switch or a referral to a different pharmacy. The injectable shortage, however, remains a systemic challenge requiring institutional-level contingency planning.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
